Summary
A research-focused overview of Ipamorelin and CJC-1295, two complementary peptides studied for their ability to stimulate pulsatile growth hormone release, support recovery, body composition, and healthy aging.
Why These Two Peptides Are Studied Together
In growth hormone research, Ipamorelin and CJC-1295 occupy complementary roles in the same signalling pathway. Understanding why researchers so frequently combine them requires a brief look at how the body naturally regulates growth hormone release.
The pituitary gland secretes growth hormone (GH) in pulses, driven by two opposing signals from the hypothalamus:
- GHRH (Growth Hormone-Releasing Hormone) — stimulates GH release
- Somatostatin — inhibits GH release
Ipamorelin acts on a separate receptor — the Growth Hormone Secretagogue Receptor (GHSR) — amplifying the GH pulse by mimicking ghrelin. CJC-1295 is a synthetic analogue of GHRH itself, extending the stimulating signal. Together, they act on two distinct receptors in the same pathway, which preclinical studies suggest produces a synergistic increase in GH output that exceeds either compound used alone.
This dual-pathway synergy is the primary reason the combination has become one of the most studied pairings in growth hormone peptide research.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide — five amino acids in length — and a selective agonist of the Growth Hormone Secretagogue Receptor (GHSR). It was developed as a third-generation GH secretagogue, improving on earlier compounds such as GHRP-2 and GHRP-6.
Its key characteristic in the research literature is selectivity. Earlier GHRPs produced significant increases not only in growth hormone but also in cortisol and prolactin — hormones that, at elevated levels, can counteract the benefits researchers are studying. Ipamorelin's selectivity means it produces a robust GH pulse with minimal effect on cortisol or prolactin, making it a cleaner research tool.
Structurally, Ipamorelin is a derivative of GHRP-1, modified to enhance receptor selectivity and half-life. Its half-life is approximately two hours, meaning it produces a defined, pulsatile burst of GH rather than sustained elevation.
What Is CJC-1295?
CJC-1295 is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), the 44-amino acid peptide naturally secreted by the hypothalamus.
The original GHRH molecule has a short half-life in circulation — approximately 7 minutes — due to rapid enzymatic degradation. CJC-1295 was engineered to resist this degradation, extending its half-life to approximately 30 minutes in its standard form (without DAC — Drug Affinity Complex).
The version studied most frequently in combination with Ipamorelin is CJC-1295 without DAC, also known as modified GRF(1-29). This version provides a meaningful half-life extension over native GHRH while preserving the pulsatile nature of GH release.
The DAC version of CJC-1295 binds to albumin in circulation, extending its half-life to approximately one week. This produces a prolonged elevation of growth hormone and IGF-1, which some research protocols have studied, but it blunts the natural pulsatile release pattern that many researchers consider more physiologically appropriate.
The Growth Hormone Pulse
Understanding why pulsatile GH release matters is central to interpreting this research area.
Growth hormone does not act continuously in the body. It is released in discrete pulses — most prominently during deep sleep, exercise, and periods of metabolic stress. These pulses trigger downstream signalling, most importantly the production of Insulin-like Growth Factor 1 (IGF-1) in the liver.
IGF-1 is the primary mediator of many of the tissue-level effects attributed to growth hormone. It promotes:
- Cell proliferation and differentiation
- Protein synthesis in muscle tissue
- Lipolysis (fat breakdown)
- Bone density maintenance
- Collagen synthesis in connective tissue
Research with Ipamorelin and CJC-1295 consistently focuses on measuring whether these compounds produce GH and IGF-1 increases that mimic the body's natural pulsatile pattern, rather than the sustained supraphysiological elevations associated with exogenous recombinant GH (rHGH).
Body Composition Research
The relationship between growth hormone, IGF-1, and body composition has been extensively studied.
In animal models and early-phase human studies examining GH secretagogues, researchers have observed:
Lean Muscle Mass
IGF-1 stimulates protein synthesis and inhibits protein breakdown in skeletal muscle. Studies investigating GH secretagogues, including Ipamorelin in preclinical models, have reported increased lean muscle mass in treated groups versus controls.
This area of research overlaps with sarcopenia — the age-related loss of muscle mass — where declining GH and IGF-1 levels are considered contributing factors.
Fat Metabolism
Growth hormone has direct lipolytic effects, promoting the breakdown of stored fat for energy — particularly visceral adipose tissue. Studies have observed reductions in fat mass alongside preservation of lean mass in models using GH secretagogue protocols.
This effect is distinct from semaglutide or tirzepatide mechanisms, which primarily act through appetite suppression and glucose regulation. GH secretagogues act upstream, through hormonal signalling rather than caloric restriction pathways.
Bone Density
IGF-1 plays a role in bone formation and maintenance. Research in ageing animal models has observed improvements in bone mineral density markers in groups receiving GH secretagogue treatment, which has driven interest in this compound class for osteoporosis-adjacent research.
Sleep and Recovery Research
One of the most consistently discussed findings in Ipamorelin research is its alignment with the body's natural GH release during sleep.
The largest natural GH pulse in a 24-hour period occurs approximately 90 minutes after sleep onset, during slow-wave (deep) sleep. Several researchers have hypothesised that administering GH secretagogues in the evening — to coincide with this natural pulse — amplifies the body's existing release pattern rather than overriding it.
Studies in animal models have examined:
- Recovery from acute tissue injury (muscle and connective tissue)
- Post-exercise repair markers
- Sleep architecture in relation to GH secretagogue administration
Results have been broadly consistent with the hypothesis that GH secretagogues enhance recovery-phase processes that are normally GH-dependent.
Ipamorelin and CJC-1295 in Ageing Research
Age-related decline in GH and IGF-1 is well-documented. By the sixth decade of life, mean 24-hour GH secretion may be reduced by more than 50% compared to young adulthood. This has been termed somatopause.
Researchers studying somatopause investigate whether GH secretagogues can safely restore more youthful GH and IGF-1 profiles without the risks associated with exogenous rHGH.
Key advantages of GH secretagogues over exogenous rHGH in research contexts include:
- Preservation of pituitary feedback mechanisms — the body's own somatostatin system continues to apply a ceiling on GH output
- Pulsatile release pattern, rather than sustained elevation
- No exogenous hormone introduced — the body produces its own GH
- Lower risk of the GH-excess effects observed with rHGH overuse
Studies examining Ipamorelin specifically in aged animal models have reported improvements in lean mass, bone density markers, and recovery metrics — findings that have sustained interest in this compound class among longevity researchers.
CJC-1295 Without DAC vs With DAC
This distinction appears frequently in research literature and deserves clear explanation.
| Property | CJC-1295 Without DAC | CJC-1295 With DAC |
|---|---|---|
| Half-life | ~30 minutes | ~7 days |
| GH release pattern | Pulsatile | Sustained/blunted |
| IGF-1 elevation | Acute, dose-dependent | Chronic, sustained |
| Research pairing | Commonly with Ipamorelin | Used alone |
| Mechanism | GHRH receptor agonism | GHRH receptor + albumin binding |
The without-DAC version is almost universally preferred in combination protocols with Ipamorelin, because its shorter duration preserves the pulsatile pattern that Ipamorelin also produces.
Ipamorelin vs Other GH Secretagogues
Ipamorelin's selectivity profile sets it apart from earlier compounds in the same class.
| Compound | GH Increase | Cortisol Increase | Prolactin Increase | Selectivity |
|---|---|---|---|---|
| Ipamorelin | Significant | Minimal | Minimal | High |
| GHRP-2 | Significant | Moderate | Moderate | Low |
| GHRP-6 | Significant | Significant | Significant | Low |
| Hexarelin | Significant | Significant | Significant | Low |
| MK-677 (Ibutamoren) | Significant | Minimal | Minimal | Moderate |
This selectivity profile is the primary reason Ipamorelin became a preferred research tool for studying GH secretion without the cortisol confound that complicated interpretation of earlier GHRP data.
Delivery and Administration in Research
Both Ipamorelin and CJC-1295 without DAC are peptides that are degraded by gastrointestinal enzymes, making oral bioavailability negligible. Research protocols have therefore used:
Subcutaneous injection — the most widely used route in published research. Provides reliable absorption and defined pharmacokinetics. Both compounds are typically lyophilised (freeze-dried) powders requiring reconstitution in sterile water before use.
Intravenous administration — used in pharmacokinetic and dose-finding studies to establish baseline data.
Intranasal administration — an emerging area of interest for peptide delivery research. The nasal mucosa provides direct vascular access and avoids gastrointestinal degradation. Bioavailability via this route is lower than subcutaneous injection but may be sufficient for certain research applications.
Safety Profile in the Research Literature
Both compounds have been examined in Phase I and Phase II clinical research settings.
Notable findings from the published literature:
Ipamorelin: Demonstrated a favourable tolerability profile in Phase I studies. No significant adverse effects on cortisol, prolactin, or ACTH were observed at research doses. The primary mechanism of action — GHSR agonism — is self-limiting due to endogenous somatostatin feedback.
CJC-1295 Without DAC: Well tolerated in preclinical models. As a GHRH analogue, it acts upstream in the hypothalamic-pituitary axis and relies on intact pituitary function to produce GH output.
Combination: No published clinical safety signals specific to the combination have been identified in the literature, though controlled human trials examining the combination remain limited.
As with all research compounds, these findings pertain to controlled settings. Neither compound is approved as a pharmaceutical treatment.
Frequently Asked Questions
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide that acts as a selective Growth Hormone Secretagogue Receptor (GHSR) agonist, stimulating pulsatile growth hormone release from the pituitary gland with minimal effect on cortisol or prolactin.
What is CJC-1295?
CJC-1295 is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH). The without-DAC version has a half-life of approximately 30 minutes and is commonly used in research to amplify pulsatile GH release.
Why are Ipamorelin and CJC-1295 studied together?
They act on two distinct receptors in the same GH-release pathway — Ipamorelin on the GHSR, CJC-1295 on the GHRH receptor. Research suggests their combination produces synergistic GH output exceeding either compound alone.
What is the difference between CJC-1295 with and without DAC?
CJC-1295 without DAC has a half-life of approximately 30 minutes and preserves pulsatile GH release. The DAC version binds to albumin, extending its half-life to approximately one week and producing sustained IGF-1 elevation.
How does Ipamorelin differ from GHRP-2 or GHRP-6?
Ipamorelin is significantly more selective. Unlike GHRP-2 and GHRP-6, it stimulates GH release without substantially elevating cortisol or prolactin.
What is somatopause?
Somatopause refers to the age-related decline in growth hormone secretion, typically accelerating after the third decade of life. It is a focus of longevity and healthy aging research.
References
Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998.
Sackmann-Sala L et al. Activation of the GH/IGF-1 axis by CJC-1295. Journal of Endocrinology. Published experimental data.
Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology and Metabolism. 2006.
Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 1998.
PubMed indexed literature relating to GHSR agonism, GHRH analogues, and pulsatile growth hormone secretion.
Research Use Only Disclaimer
BioPepTech products are supplied strictly for research use only. They are not intended for human consumption and are not intended to diagnose, treat, cure, or prevent disease.